solium [4] and [5]. Other antigens encoded by the TSOL45 gene family have not yet been evaluated for their ability to protect pigs against infection with the T. solium parasite. The TSOL16 antigen is a third T. solium antigen

type SKI-606 ic50 that has been cloned from oncospheres and the encoding gene has been characterized [8]. It was isolated from T. solium following demonstration of the ability of a homologous recombinant antigen, To16, to confer protection of vaccinated sheep against a related parasite, Taenia ovis [9]. TSOL16 appears to be specifically expressed in the oncosphere life cycle stage of T. solium [10] and is associated with penetration gland cells [11]. Although the development of a porcine vaccine based upon the TSOL18 antigen is at an advanced stage, nevertheless it remains important to evaluate the potential for other antigens to protect pigs against T. solium. For example, widespread application of a vaccine based on a single immunogen could potentially select for genetic variants of T. solium having reduced susceptibility to the vaccine. Application of a vaccine incorporating

multiple, antigenically U0126 unrelated immunogens would be expected to reduce the likelihood of selection of resistant parasites, in a manner analogous to the use of different anthelmintics to reduce selection for resistance [12]. Currently available evidence [13] does not suggest that genetic variability in the TSOL18 protein would be a problem during the initial application

of the TSOL18 vaccine, however evaluating the ability of other recombinant proteins to complement TSOL18 would add to the potential reliability of vaccination as a control measure for T. solium. The aims of this study were to evaluate whether the TSOL16 protein could be used to protect pigs against infection with T. solium and to determine whether a protein related to the TSOL45-1A antigen and encoded by Oxalosuccinic acid a splice variant lacking one of two FnIII domains (TSOL45-1B) retains the ability to protect pigs against cysticercosis. The TSOL16 cDNA was originally cloned from T. solium oncosphere mRNA as described in [8]. Two related TSOL16 cDNAs were first isolated, designated TSOL16A and TSOL16B, which differed at two positions in their predicted amino acid sequences [8]. The TSOL16A cDNA was selected for expression in Escherichia coli since the substituted amino acids were identical in sequence to To16 from T. ovis, a related antigen that has been previously shown to be host protective in sheep [9]. The encoded TSOL16A protein contains hydrophobic amino acids within a predicted secretory signal at the N-terminus. In order to enable efficient expression of the TSOL16A protein in E. coli, PCR amplification was used to produce a cDNA construct encoding a modified form of the antigen that lacked the 16 N-terminal amino acids of the secretory signal.